CreativeOne Wealth LLC Acquires 12,552 Shares of Novo Nordisk A/S (NYSE:NVO)

CreativeOne Wealth LLC increased its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 158.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 20,463 shares of the company’s stock after acquiring an additional 12,552 shares during the quarter. CreativeOne Wealth LLC’s holdings in Novo Nordisk A/S were worth $2,437,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. 1620 Investment Advisors Inc. acquired a new stake in shares of Novo Nordisk A/S in the second quarter valued at approximately $25,000. Strategic Investment Solutions Inc. IL bought a new position in shares of Novo Nordisk A/S in the second quarter worth $25,000. Gilliland Jeter Wealth Management LLC raised its position in Novo Nordisk A/S by 200.0% during the second quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock valued at $26,000 after purchasing an additional 120 shares in the last quarter. Daiwa Securities Group Inc. bought a new position in shares of Novo Nordisk A/S in the 3rd quarter valued at $28,000. Finally, Halpern Financial Inc. raised its holdings in shares of Novo Nordisk A/S by 113.0% during the 2nd quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock worth $30,000 after buying an additional 113 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 0.0 %

Shares of NYSE NVO opened at $106.12 on Thursday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. Novo Nordisk A/S has a 52-week low of $94.73 and a 52-week high of $148.15. The stock has a market cap of $476.22 billion, a P/E ratio of 34.34, a price-to-earnings-growth ratio of 1.35 and a beta of 0.42. The firm has a 50 day moving average price of $113.80 and a two-hundred day moving average price of $128.33.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on NVO. BMO Capital Markets reduced their price objective on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research note on Thursday, October 17th. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Finally, StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Novo Nordisk A/S currently has an average rating of “Buy” and an average target price of $144.50.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.